EGFR and non-small cell lung carcinoma: The IMpower 150 phase 3 trial compared Carboplatin, Paclitaxel, Bevacizumab and Atezolizumab (ABCP) with Carboplatin, Paclitaxel, Bevacizumab in advanced stage nonsquamous NSCLC patients (including those with EGFR and alterations with disease progression or unacceptable toxicity from at least one approved tyrosine kinase inhibitor); after 4 cycles of induction, Atezolizumab and Bevacizumab or Bevacizumab alone were administered until disease progression or unmanageable toxicity [64].